Galectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report) CEO Joel Lewis sold 7,829 shares of Galectin Therapeutics stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $7.06, for a total transaction of $55,272.74. Following the sale, the chief executive officer directly owned 832,592 shares of the company’s […]

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) Director Luke Evnin sold 9,983 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $1.14, for a total value of $11,380.62. Following the completion of the sale, the director owned 2,841,957 shares in the company, valued […]

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) Director Luke Evnin sold 23,640 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $1.07, for a total transaction of $25,294.80. Following the completion of the sale, the director owned 2,866,488 shares in […]

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) Director Luke Evnin sold 28,009 shares of Werewolf Therapeutics stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $1.07, for a total transaction of $29,969.63. Following the completion of the transaction, the director owned 2,907,986 shares of […]

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) Director Luke Evnin sold 17,858 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $1.08, for a total transaction of $19,286.64. Following the completion of the transaction, the director directly owned 2,890,128 shares […]

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) Director Luke Evnin sold 34,041 shares of the company’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $0.99, for a total value of $33,700.59. Following the transaction, the director directly owned 3,017,669 shares of the company’s stock, valued […]

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) Director Luke Evnin sold 16,568 shares of Werewolf Therapeutics stock in a transaction on Friday, December 5th. The stock was sold at an average price of $0.97, for a total value of $16,070.96. Following the completion of the sale, the director directly owned 3,051,710 shares of the […]

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) major shareholder Ansbert Gadicke sold 57,225 shares of the stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $0.87, for a total value of $49,785.75. Following the sale, the insider owned 4,867,341 shares of the company’s stock, valued at […]

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) major shareholder Ansbert Gadicke sold 59,277 shares of the business’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $0.89, for a total transaction of $52,756.53. Following the completion of the sale, the insider directly owned 4,924,566 shares in […]